NCT02265731View on ClinicalTrials.gov

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 22, 2014

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Acute Myeloid Leukemia (AML)
Interventions
DRUG

azacitadine

75 mg/m2 by IV infusion or subcutaneous dosing

DRUG

venetoclax

Step-up doses of venetoclax to the designated cohort dose

DRUG

rituximab / IDEC-C2B8

375 mg/m2 on Week 6

DRUG

rituximab / IDEC-C2B8

500 mg/m2 Week 10 Day 1 and thereafter

Trial Locations (14)

4678602

Nagoya City University Hospital /ID# 129278, Nagoya

9808574

Tohoku University Hospital /ID# 129275, Sendai

460-0001

NHO Nagoya Medical Center /ID# 129222, Nagoya

464-8681

Aichi Cancer Center Hospital /ID# 129061, Nagoya

910-1193

University of Fukui Hospital /ID# 165801, Yoshida-gun

811-1395

National Hospital Organization Kyushu Cancer Center /ID# 149741, Fukuoka

812-8582

Kyushu University Hospital /ID# 163202, Fukuoka

650-0047

Kobe City Medical Center General Hospital /ID# 170919, Kobe

589-8511

Kindai University Hospital /ID# 169554, Osakasayama-shi

565-0871

Osaka University Hospital /ID# 169862, Suita-shi

104-0045

National Cancer Center Hospital /ID# 129044, Chuo-ku

135-8550

The Cancer Institute Hospital Of JFCR /ID# 129277, Koto-ku

105-8470

Toranomon Hospital /ID# 148229, Minato-ku

141-8625

NTT Medical Center Tokyo /ID# 166281, Shinagawa-ku

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie

INDUSTRY